Alzamend Neuroâ˘, Inc. (âAlzamendâ˘â) is a biotechnology company dedicated to the research, development and commercialization of pharmaceuticals for the treatment and cure of Alzheimerâs disease. Alzamend Neuro⢠is currently working to transition two therapeutics targeting Alzheimerâs disease (âADâ) from the research and preclinical stage at the University of South Florida into the clinical stage and towards full commercialization. Alzamend Neuro⢠has licensed both a patented mutant-peptide immunotherapeutic (CAO22W) for use as a treatment or vaccine and a lithium based ionic cocrystal therapy (LiProSalâ˘) that may greatly reduce or eliminate the symptoms of agitation and other endpoints for mild to moderate stage patients diagnosed with AD. There are no profound treatments today for Alzheimerâs disease. With CAO22W and LiProSalâ˘, the Company believes that Alzamend⢠can change that.
